Premium
Gemcitabine and oxaliplatin combination chemotherapy for metastatic well‐differentiated neuroendocrine carcinomas
Author(s) -
Cassier Philippe A.,
Walter Thomas,
Eymard Beatrice,
Ardisson Philippe,
Perol Maurice,
Paillet Carole,
Chayvialle JeanAlain,
Scoazec JeanYves,
Hervieu Valerie,
Bohas Catherine Lombard
Publication year - 2009
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24384
Subject(s) - oxaliplatin , medicine , gemcitabine , chemotherapy , oncology , cancer , colorectal cancer
BACKGROUND: Beyond the usual regimens based on streptozocin and doxorubicin or 5‐fluorouracil, no second‐line therapy of metastatic neuroendocrine tumor has gained wide acceptance. Gemcitabine and oxaliplatin are generally well tolerated and have shown activity against a wide range of malignancies. The authors assessed the efficacy of gemcitabine‐oxaliplatin combination (GEMOX) in the treatment of patients with metastatic neuroendocrine tumors. METHODS: Twenty consecutive patients with progressive disease were treated with GEMOX, in most cases after failure of other chemotherapy regimens (median = 2). Patients were followed for evidence of toxicity, response, and survival. Two patients were chemotherapy‐naive at treatment initiation and were excluded from the efficacy analysis. RESULTS: Toxicity was manageable overall; however, 6 (30%) patients had to discontinue treatment because of oxaliplatin‐induced neurotoxicity (grade 2). Three (17%) of 18 patients had a partial response, median progression‐free survival was 7.0 months, and median overall survival was 23.4 months. CONCLUSIONS: Gemcitabine‐oxaliplatin combination shows interesting activity and is well tolerated in pretreated patients with neuroendocrine tumors. Cancer 2009. © 2009 American Cancer Society.